Article Listing - Merck & Co's Ph III cholesterol inhibitor anacetrapib meets safety and efficacy endpoints in patients with CHD

INTERFERON ALFA-N3 AND AIDS

6 April 1992

Researchers at the Walter Reed Army Institute of Research and at Interferon Sciences have commenced Phase I trials with the...

ROMANIAN HEALTH SECTOR PLANS

6 April 1992

Romania's Minister of Health, Mircea Aiorescu, has announced in Bucharest that his Ministry is planning to change various aspects of...

WALDEGRAVE GIVES MESSAGE TO UK PHARMA INDUSTY

6 April 1992

From UK Health Secretary William Waldegrave

As the UK's general election campaigning draws to a conclusion, Secretary of State for Health...

PFIZER'S DIFLUCAN

6 April 1992

Prophylactic administration of Pfizer's Diflucan (fluconazole) to recipients of autologous bone marrow transplants reduces the incidence of both systemic and...

ALLELIX BIOPHARMA: DOUGLAS FROOM

6 April 1992

Douglas Froom has been appointed as vice president for business development at Allelelix Biopharmaceuticals Inc, of Canada.

GENZYME AND CYSTIC FIBROSIS

6 April 1992

Genzyme is to exercise its option to buy rights to Neozyme's cystic fibrosis protein replacement therapeutic program, under the terms...

BLOOD BANKING AND PLASMA PRODUCTS

6 April 1992

The world market for blood banking and plasma products was valued at $2.5 billion in 1990, and is expected to...

GLAXO FRANCE CHIEF QUITS

6 April 1992

Edwin Nathan, president of Glaxo France and of the group's Belgian and Luxembourg companies, has announced his departure from the...

ARAB PHARMA COOPERATION

6 April 1992

The executive board of the Union of Arab Druggists, meeting in Cairo, has established a new system of cooperation in...

GLOBAL MARKETS AND FACTORS FOR SUCCESS

6 April 1992

As the geographical borders between pharmaceutical markets begin to disappear, so do the differences among the critical success factors for...